Anticancer Res. 2020 Nov;40(11):6473-6484. doi: 10.21873/anticanres.14669.

Authors

Koichi Mitsuya  1   2 , Yasuto Akiyama  3   2 , Akira Iizuka  1 , Haruo Miyata  1 , Shoichi Deguchi  2 , Nakamasa Hayashi  2 , Chie Maeda  1 , Ryota Kondou  1 , Akari Kanematsu  1 , Kyoko Watanabe  1 , Tadashi Ashizawa  1 , Yoshiaki Abe  4 , Ichiro Ito  5 , Takuma Oishi  6 , Takashi Sugino  6 , Yoko Nakasu  2 , Ken Yamaguchi  7

Affiliations

 

    1 Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

    2 Division of Neurosurgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

    3 Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka Cancer Center Hospital, Shizuoka, Japan y.akiyama@scchr.jp.

    4 Division of Blood Transfusion,, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

    5 Division of Pathology, Nagano Red Cross Hospital, Nagano, Japan.

    6 Division of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

    7 Office of the President, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

 

    PMID: 33109586

    DOI: 10.21873/anticanres.14669 

 

Abstract

 

Background/aim: Glioblastoma multiforme (GBM) is an intractable tumor that has a very poor prognosis despite intensive treatment with temozolomide plus radiotherapy.

 

Patients and methods: Sixteen newly diagnosed patients with high-grade gliomas were enrolled in a phase II study of the α-type-1 DC vaccine. Briefly, DCs obtained from the culture of enriched monocytes in the presence of a cytokine cocktail, were pulsed with a cocktail of 5 synthetic peptides and cryopreserved until injection into patients.

 

Results: The amount of IL-12 produced by activated DCs was higher than that previously reported. Among 15 evaluable patients, 10 showed positive CTL responses to any peptides in an ELISPOT assay. After 6 years of observation, five patients were still alive, and two of these patients were relapse-free. Moreover, a significant survival-prolonging effect was verified in DC-treated glioma patients.

 

Conclusion: Peptide-cocktail-pulsed α-type-1 DC vaccines have a potential therapeutic effect on survival when used in combination with the standard regimen, which is partly based on IL-12-IFN-γ-mediated T-cell activation.

 

Keywords: Activated dendritic cell; HLA-A24; high-grade glioma; immunotherapy; phase II trial.

 

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.